HOME >> BIOLOGY >> NEWS
Drug-naive schizophrenia: The dopamine connection

Since the introduction of chlorpromazine in psychiatry in 1952, all antipsychotic drugs with proven efficacy have been dopamine (DA) D2 receptor antagonists. It has been suggested that positive schizophrenic symptoms (such as hallucinations) are associated with increased subcortical DA neurotransmission, and negative and cognitive symptoms with impaired mesocortical DA function. Studies on striatal D2 receptor densities in drug-naive schizophrenic patients have indicated that deviation in D2 density is larger among patients vs. controls, and although some patients have markedly elevated D2 levels, the D2 densities do not differ substantially at group level. Although DA neurotransmission in basal ganglia may be more important for motor functions rather than for emotions and behavioral symptoms, D2 binding studies have previously concentrated in the striatum, because there have been no suitable in vivo -ligands available for measuring extrastriatal D2 receptor binding. The aim of this study was to test the hypothesis that extrastriatal D2/3 density in temporal and cingulate cortex is lower among drug naive schizophrenic patients when compared with matched controls.

The results indicate that in drug-naive schizophrenic patients the extrastriatal dopamine D2/3 receptor density is markedly decreased. The authors also observed negative correlations between D2/3 receptor density and age among controls, and between D2/3 density and negative and general psychopathological symptom scores among patients. These results support the previous hypothesis on dysfunction of mesocortical dopamine function behind the cognitive and negative symptoms in schizophrenia.


'"/>

Contact: Aimee Midei
molecularpsychiatry@mednet.ucla.edu
310-206-6739
Molecular Psychiatry
12-May-2003


Page: 1

Related biology news :

1. Cognitive therapy for schizophrenia: Hope for those whom drugs havent helped
2. Vollum scientists find new form of dopamine transmission
3. How amphetamine affects the dopamine transporter
4. The dopamine receptor D1 gene and ADHD: A piece of the genetic puzzle?
5. Jefferson scientists show neural stem cells can become dopamine-making brain cells in laboratory
6. Molecule awakens and maintains neural connections
7. The Mediterranean connection: ecological effects of El Nio in the Northern hemisphere
8. OHSU researchers discover possible connection between infant hormone exposure, obesity
9. Gene essential for development of normal brain connections resulting from sensory input discovered
10. K-State professor examines connections between food, culture and psychology in new book
11. New study clarifies connection of brain and heart failure

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drug naive schizophrenia The dopamine connection

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: